Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyle Bryan

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
AMA Journal of Ethics|September 4, 2020
What Does Good Pharmacist-Physician Pain Management Collaboration Look Like?Kyle Bryan, Thomas E Menighan
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2015
Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337)Gregory N Dietsch, Tressa D Randall, Raphael Gottardo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2016
Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHNLaura Q M Chow, Chihiro Morishima, Keith D Eaton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2017
Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid SignalsGulidanna Shayan, Benjamin A Kansy, Sandra P Gibson, et al.
JAMA Oncology|June 23, 2018
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical TrialRobert L Ferris, Nabil F Saba, Barbara J Gitlitz, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
AMA Journal of Ethics|September 4, 2020
What Does Good Pharmacist-Physician Pain Management Collaboration Look Like?Kyle Bryan, Thomas E Menighan
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2015
Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337)Gregory N Dietsch, Tressa D Randall, Raphael Gottardo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2016
Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHNLaura Q M Chow, Chihiro Morishima, Keith D Eaton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2017
Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid SignalsGulidanna Shayan, Benjamin A Kansy, Sandra P Gibson, et al.
JAMA Oncology|June 23, 2018
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical TrialRobert L Ferris, Nabil F Saba, Barbara J Gitlitz, et al.
Pageof 1